Diamyd Medical provides update on Strategic Review

▤ Summary

Diamyd Medical says it will finish closing out its Phase 3 program and then shift attention to how it can use its cash position to create long-term shareholder value. The company is open to investments, partnerships, and strategic opportunities both inside and outside healthcare. It will keep operating its GMP-certified biomanufacturing facility in Umeå and look for acquirers, customers, partners, and projects that can use that capability. The company also plans to protect the value of its precision medicine platform and intellectual property while seeking external funding for future GAD-based therapy development.

▦ Linked Companies